A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants - Zhu, Qing; McLellan, Jason S; Kallewaard, Nicole L; Ulbrandt, Nancy D; Palaszynski, Susan; Zhang, Jing; Moldt, Brian; Khan, Anis; Svabek, Catherine; McAuliffe, Josephine M; Wrapp, Daniel; Patel, Nita K; et al. (Science translational medicine, 2017)
Keywords: Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Antiviral Agents - pharmacokinetics; Antiviral Agents - therapeutic use; Female; Humans; Infant; Infant, Newborn; Male; Palivizumab - pharmacokinetics; Palivizumab - therapeutic use; Respiratory Syncytial Virus Infections - drug therapy; Respiratory Syncytial Virus Infections - prevention & control; Respiratory Syncytial Virus Vaccines - therapeutic use; Respiratory Syncytial Viruses - drug effects; Respiratory Syncytial Viruses - pathogenicity